Transabdominal lumbar approach (TALA) versus retroperitoneal approach for robot-assisted renal surgery: a prospective randomised controlled trial.

World J UrolSep 15, 2026 (epub)
Clinical ResearchUrologyGeneral SurgeryOpen access

Uwe Bieri, Franziska Heining, Aydin Javadov et al.

✦ AI-curated · Sources linked

In 30 seconds

This prospective randomized controlled trial compared the transabdominal lumbar approach (TALA) to the conventional retroperitoneal approach (RP) for robot-assisted renal surgery in 40 patients. TALA demonstrated a median time saving of 16 minutes for renal artery identification (38 vs. 54 min, p = 0.001), while maintaining comparable perioperative safety.

Key findings

  • TALA reduced the median time to renal artery identification by 16 minutes compared to RP (38 vs. 54 min, p = 0.001).
  • Perioperative safety was similar between TALA and RP, with 7.5% of patients experiencing Clavien-Dindo grade III-IV complications.
  • The study included 40 patients, with 18 undergoing TALA and 22 undergoing RP.

Why it matters

Understanding the efficiency and safety of different surgical approaches is crucial for optimizing patient outcomes in robotic nephrectomy. This study provides evidence that TALA may enhance surgical efficiency without compromising safety.

Source

PubMed · PMID 42742659Free full text on PubMed Central

Published in World J Urol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.